- 1
“= Ozempic® · Wegovy®” brand comparison.→ Trademark + comparative-Rx claim (Novo).
- 2
Product titled “Semaglutide”.→ Open INN drug name = processor termination.
- 3
“GLP-1 agonist for weight loss — suppresses appetite”.→ Drug class + mechanism + weight-loss human-use claim.
- 4
“4.9 ★ · 4,892 reviews”.→ Fake-review-rule exposure (16 CFR 465).
- 5
“Save 93% vs pharmacy”.→ Cheaper-Rx-substitute = intended human use.
- 6
“Choose format: injectable pen / oral tablets”.→ Human dosage forms = intended-use trap.
- 7
“FDA Approved” badge.→ False/implied endorsement.
- 8
“100% safe, no side effects”.→ Unsubstantiated safety claim.
- 9
“Discreet, unmarked packaging”.→ Concealment signal.
- 10
“Treats obesity & reverses type 2 diabetes”.→ Disease claims = unapproved new drug.
- 11
Dosing titration + “how to inject”.→ Human-use dosing/administration.
- 12
Before/after + testimonials.→ Human-use proof + endorsements; no RUO/COA/specs anywhere.